Arvinas (NASDAQ:ARVN) Downgraded to “Sell” Rating by Wall Street Zen

Arvinas (NASDAQ:ARVN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

Other analysts have also issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Wedbush lifted their price target on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Citigroup raised shares of Arvinas from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $10.00 to $15.00 in a research report on Tuesday, January 6th. Stephens raised their target price on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Finally, Wells Fargo & Company decreased their target price on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Ten research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.47.

Arvinas Stock Performance

NASDAQ ARVN opened at $13.27 on Monday. The firm’s fifty day moving average price is $12.48 and its two-hundred day moving average price is $10.65. The stock has a market cap of $848.75 million, a PE ratio of -10.37 and a beta of 1.87. Arvinas has a fifty-two week low of $5.90 and a fifty-two week high of $18.93.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The firm had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. During the same period in the previous year, the business posted ($0.63) earnings per share. The business’s revenue for the quarter was down 84.0% compared to the same quarter last year. As a group, sell-side analysts predict that Arvinas will post -3.81 earnings per share for the current fiscal year.

Insider Activity at Arvinas

In other news, CFO Andrew Saik sold 5,134 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the transaction, the chief financial officer directly owned 159,267 shares of the company’s stock, valued at $1,893,684.63. This represents a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Randy Teel sold 4,786 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the completion of the transaction, the chief executive officer directly owned 149,696 shares in the company, valued at approximately $1,820,303.36. This represents a 3.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 22,132 shares of company stock valued at $264,741 over the last ninety days. Corporate insiders own 4.73% of the company’s stock.

Institutional Trading of Arvinas

Several hedge funds have recently made changes to their positions in the company. Armistice Capital LLC lifted its holdings in shares of Arvinas by 50.0% in the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock worth $21,348,000 after buying an additional 600,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in Arvinas during the 3rd quarter worth approximately $13,780,000. Geode Capital Management LLC lifted its stake in Arvinas by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock worth $11,668,000 after purchasing an additional 48,296 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock valued at $12,668,000 after purchasing an additional 903,337 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after purchasing an additional 1,267,593 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling meaningful upside versus current levels. Read More.
• Positive Sentiment: HC Wainwright raised longer‑range earnings projections for FY2028–FY2030 (FY2028 to $3.09, FY2029 to $1.76, FY2030 to $5.60), implying stronger late‑cycle profitability if clinical/program milestones are met. Read More.
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Ikarian among buyers), which can support liquidity and indicate some investor confidence in the pipeline. Read More.
• Neutral Sentiment: Street consensus remains mixed (MarketBeat shows a “Hold” consensus with a $13.47 average target), so analyst moves are not uniform — upgrades from some firms may not sway broader sentiment. Read More.
• Neutral Sentiment: Reported short‑interest figures in recent updates appear to be erroneous (showing 0 shares/NaN), so short‑interest/read‑through risk is unclear until corrected data is published. (data report)
• Negative Sentiment: HC Wainwright sharply cut near‑term estimates (Q1–Q4 2026 and FY2026/FY2027 EPS downgraded), lowering expected profitability this year and next — a near‑term negative catalyst for the stock. Read More.
• Negative Sentiment: Q4 2025 results were a clear negative: EPS and revenue missed materially (reported -$1.10 EPS vs. -$0.55 expected; revenue $9.5M vs. $37.3M expected), which is the primary driver pressuring the share price. Read More.
• Negative Sentiment: Insider sales: CEO Randy Teel and CAO David Loomis sold shares on Feb. 23 (modest reductions). Insider selling can be perceived negatively even when routine; filings: Read More., Read More.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.